MassDevice1d
Anaconda Biomed enrolls first patient in study of funnel catheter for treating stroke
Anaconda Biomed announced the enrollment and treatment of the first U.S. patient in a clinical trial of its ANA Funnel ...
Exempt or Not, the Chip Industry Won’t Escape Tariffs
Higher prices for the many products that contain chips threaten to hit demand.
MedTech Dive2d
AdvaMed repeats call for tariff exemption as new levies threaten healthcare supply chain
Lobby groups like AdvaMed and the American Hospital Association have so far failed to get medical devices and critical ...
Targeted Oncology2d
FDA Approves IDE Application for Alpha DaRT in Recurrent Glioblastoma
The FDA has approved an investigational device exemption (IDE) application for the start of a pilot study evaluating the Alpha diffusing alpha-emitters radiation therapy (DaRT) technology in patients ...
CURE3d
FDA Approves Initiation of a New Trial in Recurrent Glioblastoma
The FDA has approved an application to initiate a pilot study with Alpha DaRT for patients with recurrent glioblastoma, a ...
Alpha Tau receives FDA approval to start trial for patients with recurrent GBM
Medical announced that the FDA has approved an Investigational Device Exemption, IDE, application to initiate a pilot study ...
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma
Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, ...
Medical Device Network on MSN4d
FDA clears Bolt Medical’s IVL system, backing Boston Scientific’s $664m buyout
The intravascular lithotripsy market has undergone high growth trailblazed by J&J subsidiary Shockwave Medical.
Drug Delivery Business4d
Glucotrack expects FDA IDE for implantable CBGM this year
Glucotrack (Nasdaq:GCTK) announced that it expects FDA investigational device exemption for its long-term CBGM later this ...
Le Lézard4d
JointMedica Announces Launch of IDE Study for Polymotion® Hip Resurfacing System
JointMedica, a global leader in orthopedic innovation, announces the commencement of an Investigational Device Exemption (IDE) study for its Polymotion® Hip Resurfacing (PHR®) device. The IDE study ...
The Manila Times4d
Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation
Full REMAIN-1 pivotal study enrollment anticipated in summer 2025 ...